Skip to Main Content

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure

Conditions

Diseases of the Blood | Diseases of the Cardiovascular System

What is the purpose of this trial?

Primary Objectives:

  • Assess the safety and tolerability of sotagliflozin in hemodynamically stable patients hospitalized for worsening of heart failure.
  • Estimate the effects of sotagliflozin on plasma volume changes in hemodynamically stable patients hospitalized for worsening of heart failure.

Secondary Objectives:

  • Explore the effect of sotagliflozin on erythropoiesis, as assessed by changes in plasma erythropoietin levels, in hemodynamically stable patients hospitalized for worsening of heart failure, compared to placebo.
  • Explore the effect of sotagliflozin on changes in plasma NT-proBNP levels, in hemodynamically stable patients hospitalized for worsening of heart failure, compared to placebo.
  • Trial with
    Sanofi
  • Start Date
    12/03/2017
  • End Date
    07/30/2019
Trial Image

For more information about this study, contact:

Jennifer Tainsh

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/22/2018
  • Study HIC
    #2000020192